Nancy A. Grygiel, an insider at Amgen Inc (AMGN), recently sold 7,225 shares of the company for $2.44 million at a price of $337.26 per share on November 19, 2025. Following this transaction, Grygiel retains an equal number of shares in the biotechnology firm.
Amgen, headquartered in Thousand Oaks, California, specializes in the discovery, development, manufacture, and marketing of human therapeutics. The company employs approximately 28,000 people and focuses on addressing high unmet medical needs through innovative solutions. Its product portfolio includes well-known medications such as EPOGEN, Neulasta, and Repatha, among others.
This sale underscores the complexities of insider trading, which can stem from various personal reasons, such as diversification or tax planning. While significant selling activity may attract investor attention, it does not inherently signal a negative outlook on the company.
The Securities and Exchange Commission (SEC) requires that insider transactions be reported, providing transparency regarding executives' perspectives on their stock. However, investors should analyze patterns of insider activity over time and across multiple insiders to gain a more comprehensive view, rather than relying on isolated transactions.
As of November 20, 2025, Amgen boasts a market capitalization of $184.4 billion, a P/E ratio of 26.32, and an EPS of 12.94. The company is expected to announce its next earnings on August 3, 2026, with an estimated EPS of $5.80 and revenue of $9.5 billion.